Hepatic impairment No dose adjustment is required in people with moderate or reasonable (Child-Pugh A or B) hepatic impairment (see section five.two). Exposure to midostaurin and its Lively metabolite CGP62221 is substantially decreased in people with significant hepatic impairment than that in sufferers with regular hepatic purpose (see area five. https://richardn429dim2.eqnextwiki.com/user